Zantac / Ranitidine (NDMA Cancer) Attorney in San Francisco, California

Zantac Litigation in San Francisco

San Francisco Superior Court applies California's Frye/Kelly expert admissibility standard — a general acceptance test distinct from Daubert and comparable to Delaware's standard. Multiple San Francisco Zantac cases have survived defense motions to exclude causation experts, allowing cases to proceed to trial and settlement. UCSF Helen Diller's NDMA research capabilities also make San Francisco a center of Zantac causation science. The federal Zantac MDL (No. 2924, S.D. Florida) was largely dismissed in 2022 after Judge Robin Rosenberg excluded plaintiffs' causation experts under Daubert. However, the Delaware Superior Court under Judge Vivian Medinilla continues to actively hear Zantac cases and has allowed causation experts to proceed. Defendants Sanofi, Boehringer Ingelheim, GSK, and Pfizer are all actively litigating in Delaware. For most claimants, filing in Delaware Superior Court through national plaintiffs' counsel is now the primary path forward.

Resources for San Francisco Zantac Claimants

San Francisco-area Zantac claimants should obtain pharmacy records from Walgreens (SF is home to Walgreens Boots Alliance West Coast operations), CVS, and independent pharmacies in the Bay Area. UCSF Diller Center and CPMC records documenting cancer diagnosis, staging, and treatment are critical evidence. California's 2-year SOL with discovery rule governs filing windows; San Francisco plaintiffs' bar includes firms with active Zantac coordination.